Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on advanced cancers in early trial

NCT ID NCT07399769

Recruiting now Disease control Sponsor: Shenzhen University General Hospital Source: ClinicalTrials.gov ↗

First seen Feb 16, 2026 · Last updated Jun 07, 2026 · Updated 20 times

Summary

This study tests a new treatment called MSLN CAR-T for people with advanced solid tumors that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to target a protein called MSLN found on tumor cells. Up to 20 adults will receive chemotherapy before the cell infusion to help the cells work better. The main goal is to see if the treatment is safe and to get an early look at whether it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANT TUMORS (WITH POSITIVE EXPRESSION OF MSLN IN TUMOR TISSUE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shenzhen University General Hospital

    RECRUITING

    Shenzhen, Other (Non U.s.), 518055, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANT TUMORS (WITH POSITIVE EXPRESSION OF MSLN IN TUMOR TISSUE)